|
Drugmaker GSK PLC on Friday said its vaccine candidate for respiratory syncytial virus, or RSV, showed positive phase three data in older adults.
The study, involving 25,000 participants from 17 countries, showed its candidate AReSVi 006 had a ‘statistically significant and clinically meaningful efficacy in adults aged 60 years and above’.
One dose of its candidate elicited strong ‘cellular immune responses, which remain above pre-vaccination levels up to at least the six months post-vaccination,’ GSK explained. ‘The magnitude of effect observed was consistent across RSV A and B strains’.
RSV is a common contagious virus affecting the lungs and breathing passages with no vaccines currently available for treatment.
‘RSV remains one of the few major infectious diseases without a vaccine, and these data have the potential to meaningfully impact the treatment of RSV and may reduce the 360,000 hospitalisations and more than 24,000 deaths worldwide each year,’ said Hal Barron, chief scientific officer & president of GSK's research & development arm.
The London-based pharmaceutical company expects regulatory submissions for potential approval in the second half of 2022.
GSK shares were 2.4% higher at 1,750.20 pence each in London on Friday morning, the best performer in the FTSE 100.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
